secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001558370-24-014005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend
--------------------------------------------------------------------------------

- Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.
- Raises FY 2024 GAAP EPS guidance to $1.49-$1.52 (from $1.37-$1.47) and Non-GAAP to $1.64-$1.67 (from $1.52-$1.62).
- Declares regular quarterly cash dividend of $0.15/share, payable Nov 25, 2024 to holders of record Nov 15, 2024.
- Q3 cash flow from operations was $9.1M, vs $1.4M in prior year; new Orlando facility capex ~$9M remaining.
- Q4 2024 guidance: revenue $18.8M-$19.2M, GAAP EPS $0.39-$0.42, Non-GAAP EPS $0.42-$0.45.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000155837024014005/0001558370-24-014005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000155837024014005/irmd-20241031x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer